Cara L. Haymaker

Cara L. Haymaker

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center

Affiliated withUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer Center

Research Area

Immunology and InfectionCancer Research

Biography

Cara L. Haymaker has not added Biography.
If you are Cara L. Haymaker and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

Article
Total : 2
Year
<em>In Vivo</em> Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model
Publication title
2017
2022

Other Publications

Article
Year
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

BMC medicine| PubMed ID: 27776519

2016
2017
2017
Multifaceted Role of BTLA in the Control of CD8(+) T-cell Fate after Antigen Encounter.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 28754817

2017
4-1BB Agonist Focuses CD8(+) Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 28947567

2017
2018
2019
2020
2020
T-cell agonists in cancer immunotherapy.

Journal for immunotherapy of cancer| PubMed ID: 33020242

2020
2022
2021
2021
Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.

Clinical cancer research : an official journal of the American Association for Cancer Research| PubMed ID: 34426439

2021
Engineered T-cell Receptor T Cells for Cancer Immunotherapy.

Cancer immunology research| PubMed ID: 34728535

2021
Effector memory cytotoxic CD3/CD8/CD45RO T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc| PubMed ID: 34839351

2021
2022
2022
2022
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.

Cancer immunology research| PubMed ID: 35362046

2022